Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:

NCT ID: NCT01780935 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration

OCTAVE
Start date: June 2013
Phase: Phase 3
Study type: Interventional

This study will evaluate and compare two individualized ranibizumab treatment regimens in patients with neovascular (wet) AMD aiming to achieve and to maintain a maximum visual function benefit, while aiming to avoid unnecessary intravitreal injections. The results will be used to generate further recommendations on functional and anatomical monitoring of the disease and timing of treatment administration for patients with neovascular AMD. In this context, the study will investigate the utility of optical coherence tomography (OCT) to aid retreatment decisions with ranibizumab.

NCT ID: NCT01775124 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

DRAGON
Start date: February 22, 2013
Phase: Phase 4
Study type: Interventional

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

NCT ID: NCT01722045 Completed - Clinical trials for Age - Related Macular Degeneration (AMD)

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

RE-VIEW
Start date: November 2012
Phase: Phase 4
Study type: Interventional

This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.

NCT ID: NCT01712035 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

NVAMD
Start date: October 2012
Phase:
Study type: Observational

Age-related macular degeneration (AMD) is the leading cause of blindness in non-Hispanic white Americans. Neovascular AMD is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. The presence of choroidal neovascular membrane (CNV) formation is the hallmark feature of neovascular AMD. Choroidal neovascular membranes consist of buds of neovascular tissue and accompanying fibroblasts from the choroid perforating Bruch's membrane with extension either above or below the retinal pigment epithelium. These neovascular complexes are associated with hemorrhage, fluid exudation and fibrosis formation resulting in photoreceptor damage and vision loss. Treatment of neovascular AMD consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. OCT is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time. It is analogous to ultrasound B-mode imaging, except that OCT measures the intensity of reflected light rather than acoustical waves. This observational study will use OCT technology to study and compare the retinal and choroidal anatomy and blood flow in two groups of patients with neovascular AMD: treatment naïve group and active treatment group. The purpose of this study is to assess the utility of OCT angiography in the evaluation of NVAMD.

NCT ID: NCT01682382 Completed - Clinical trials for Age-related Macular Degeneration

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

Start date: August 2012
Phase: N/A
Study type: Observational

Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there is an association between genetics, MPOD and the risk of progression to wet AMD.

NCT ID: NCT01678963 Completed - Clinical trials for Neovascular Age Related Macular Degeneration

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Start date: November 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of topical ophthalmic squalamine lactate eye drops in treating patients with neovascular age-related macular degeneration (wet AMD), a degenerative retinal eye disease that causes a progressive, irreversible, severe loss of central vision.

NCT ID: NCT01674569 Completed - Clinical trials for Exudative Macular Degeneration

Pilot Study of X-82 in Patients With Wet AMD

Start date: October 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD). Preliminary efficacy will be assessed by change from baseline in visual acuity, fluorescein leakage, retinal thickness and fibrosis, if detectable, based on fundus examination, fundus photography, fluorescein angiography and optical coherence tomography (OCT).

NCT ID: NCT01666821 Completed - Geographic Atrophy Clinical Trials

A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population

Start date: May 2004
Phase: N/A
Study type: Observational

To investigate pathomorphological and functional variations of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a Chinese population using optical coherence tomography (OCT) to find which kinds of Fundus characteristics indicated exudative AMD.

NCT ID: NCT01655589 Recruiting - Clinical trials for Macular Degeneration

VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

Start date: January 2008
Phase: N/A
Study type: Observational

The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

NCT ID: NCT01624636 Terminated - Clinical trials for Neovascular Age-related Macular Degeneration

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)